Literature DB >> 6401168

Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat.

K Ormstad, S Orrenius, T Låstbom, N Uehara, J Pohl, J Stekar, N Brock.   

Abstract

The synthetic low-molecular-weight thiol, 2-mercaptoethanesulfonate (mesna), exerts efficient protection against oxazaphosphorine-induced urothelial toxicity by binding the renally excreted and concentrated toxic metabolite(s). In this study, the pharmacokinetics and metabolism of mesna and its disulfide form (dimesna) have been investigated in the intact rat and in several in vitro systems, including isolated perfused organs, freshly isolated cells, and subcellular fractions; the mechanism of reduction of dimesna to form the pharmacologically active thiol mesna has been further studied with purified enzyme preparations. The results may be summarized as follows: (a) After p.o. administration, mesna and dimesna are both absorbed from the intestine, and dimesna undergoes reduction to mesna during intestinal absorption; (b) when present in plasma, mesna is rapidly oxidized to dimesna by a metal-dependent reaction; (c) mesna and dimesna pass unchanged through the hepatic vasculature, are not taken up into liver cells, and are not excreted in bile; (d) in the kidney, dimesna is filtered through the glomeruli and subsequently reabsorbed, whereupon reduction to the pharmacologically active thiol form occurs in the renal tubular epithelium, and the thiol is then reexcreted into the tubular lumen; (e) reduction of dimesna to mesna occurs in intestinal and renal epithelial cells by a mechanism involving the cytosolic enzymes thiol transferase and glutathione reductase. Thus, the formation of the pharmacologically active thiol form from dimesna is associated with the consumption of equimolar concentrations of reduced glutathione.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6401168

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  The stability of mesna in beverages and syrup for oral administration.

Authors:  M P Goren; B A Lyman; J T Li
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Cellular glutathione as a protective agent against 4-hydroperoxycyclophosphamide cytotoxicity in K-562 cells.

Authors:  R H Peters; K Ballard; J E Oatis; D J Jollow; R K Stuart
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Prevention of cyclophosphamide-induced urotoxicity by reduced glutathione and its effect on acute toxicity and antitumor activity of the alkylating agent.

Authors:  O Tofanetti; E Cavalletti; A Besati; G Pratesi; G Pezzoni; F Zunino
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Formation, toxicity and inactivation of acrolein during biotransformation of cyclophosphamide as studied in freshly isolated cells from rat liver and kidney.

Authors:  Y Ohno; K Ormstad
Journal:  Arch Toxicol       Date:  1985-06       Impact factor: 5.153

5.  Ifosfamide toxicity in cultured proximal renal tubule cells.

Authors:  James Springate; Mary Taub
Journal:  Pediatr Nephrol       Date:  2006-10-27       Impact factor: 3.714

6.  In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro.

Authors:  Zeinab Yaseen; Christian Michoudet; Gabriel Baverel; Laurence Dubourg
Journal:  Pediatr Nephrol       Date:  2008-01-18       Impact factor: 3.714

7.  Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Authors:  Ryan J Hansen; Susan M Ludeman; Sari J Paikoff; Anthony E Pegg; M Eileen Dolan
Journal:  DNA Repair (Amst)       Date:  2007-05-07

8.  Oral bioavailability of mesna tablets.

Authors:  B Stofer-Vogel; T Cerny; M Borner; B H Lauterburg
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.

Authors:  R C Stuart-Harris; P G Harper; C A Parsons; S B Kaye; C A Mooney; N F Gowing; E Wiltshaw
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

10.  Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols.

Authors:  N Brock; P Hilgard; J Pohl; K Ormstad; S Orrenius
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.